BFM
LPCN icon

Boothbay Fund Management’s Lipocine LPCN Stock Holding History

Boothbay Fund Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Hold
140,487
– – ﹤0.01% 1669
2026
Q1 		$1.12M Buy
140,487
+85,594
+156% +$746K 0.01% 893
2025
Q4 		$441K Buy
+54,893
New +$185K 0.01% 1214

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Boothbay Fund Management's LPCN Position: Q2 2026 in Review

Boothbay Fund Management held its Lipocine (LPCN) position steady in Q2 2026 at 140,487 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Boothbay Fund Management first reported a position in LPCN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.12M in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Boothbay Fund Management held 140,487 shares of Lipocine worth $360K as of Q2 2026.
  • Boothbay Fund Management left its Lipocine share count unchanged in Q2 2026.
  • Lipocine made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1669 holding.
  • Boothbay Fund Management first reported a position in Lipocine in Q4 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's Lipocine position peaked at $1.12M in Q1 2026.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.